New York City, New York, March 17, 2016: Persistence Market Research (PMR) has recently announced the publication of a research report on the global next-generation antibody therapeutics market. According to the report, titled “Global Next-generation Antibody Therapeutics Market Expected to Progress US$ 6,761.1 Million by 2022”, the next-generation antibody therapeutics market is projected to expand at a healthy CAGR of 13% between 2014 and 2022 and reach a market value of US$6,761.1 million by 2022. For 2015, analysts at PMR have projected a market value of US$2,250.0 million.
North America emerged as the global leader among all the regional markets for next-generation antibody therapeutics. The regional market is expected to develop at a CAGR of 14.5% during the forecast period and attain a market value of US$1,104.4 million by 2015 and US$3,691.8 million at the end of the forecast period.
Apart from this, the next-generation antibody therapeutics market in Asia is expected to report a significant growth rate. The rapid rise in the economic condition of various emerging economies in Asia, such as India and China, has enabled consumers to spend more on health-related issues. The rising incidence of various diseases and the advancement in antibody technologies, together with continuous improvement in therapeutic antibodies, is expected to fuel the growth of the next-generation antibody therapeutics market in this region, as per the report.
The research report discusses the prevalent trends in the global next generation antibody therapeutics market. Most of the development in the global next-generation antibody therapeutics market is on account of the developments in antibody technology and several initiatives taken by various governments, encouraging the uptake of these technologies.
The global increase in the incidence of various chronic diseases, the rise in the adoption of therapeutic antibodies, the development and innovation of new drugs, and the rise in research and development activities for preparing new therapies are the major ongoing trends that are boosting the rise of the market for next-generation antibody therapeutics across the world.
Interested in report: Please follow the below links to meet your requirements; Request for the Report Sample: http://www.persistencemarketresearch.com/samples/3713
Other than these, the growing demand for better medical and healthcare facilities and the rapid rise in biosimilar antibodies are projected to create ample opportunities for the global next-generation antibody therapeutics market participants.
Request TOC (table of content), Figures and Tables of the Report: http://www.persistencemarketresearch.com/toc/3713
On the other hand, several strict rules and regulations pertaining to the usage of antibodies have been imposed by various governments, which are hampering the global market for next-generation antibody therapeutics to a significant extent. Additionally, high investment required for R&D activities and the preference for older-generation drug therapies among medical and healthcare professionals as well as patients are some of the major issues facing the global market during the forecast period.
For more info: http://www.persistencemarketresearch.com/contact-us.asp
Major companies in the global next-generation antibody therapeutics market are aiming at introducing new and innovative products prepared using advanced technologies. The report has profiled several major players operating in this global market to present the completive landscape. Seattle Genetics, ImmunoGen, Bristol-Myers Squibb, Bayer, Biogen, Amgen, AstraZeneca, Pfizer, Takeda Pharmaceuticals, Kyowa Hakko Kirin, F. Hoffmann-La Roche, Xencor, and Dyax are some of the key participants of this market.
Browse full PDF: Next Generation Antibody Therapeutics Market